Philippines News API

{
    "totalArticles": 236606,
    "articles": [
        {
            "id": "3a60cc09aa007e81b91b126f826a0242",
            "title": "CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab",
            "description": "CytoDyn is a publicly traded clinical stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is…",
            "content": "VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (\"CytoDyn\" or the \"Company\"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with... [3776 chars]",
            "url": "https://www.cytodyn.com/newsroom/press-releases/detail/656/cytodyn-closes-17-5-million-financing-to-fund-continued",
            "image": "https://d1io3yog0oux5.cloudfront.net/_4a5da93e1fbda642525e309217493120/cytodyn/db/212/1910/social_image_resized.jpg",
            "publishedAt": "2026-03-05T13:32:59Z",
            "lang": "en",
            "source": {
                "id": "3618e4241928fbe8f767552bdec100d1",
                "name": "CytoDyn Inc.",
                "url": "https://www.cytodyn.com"
            }
        },
        {
            "id": "03b8ce0abe8f803b69739e3e2b496a69",
            "title": "Gulf issuers face security premium but bounceback could be swift",
            "description": "The sell-off since war broke out has not been huge",
            "content": "The sell-off since war broke out has not been huge\nUnlock this article.\nThe content you are trying to view is exclusive to our subscribers.\nTo unlock this article:\nRequest demo or Login\n✔ 4,000 annual insights\n✔ 700+ notes and long-form analyses\n✔ 4 ... [449 chars]",
            "url": "https://www.globalcapital.com/article/2g2dz697pzumck8whiozk/emerging-markets/gulf-issuers-face-security-premium-but-bounceback-could-be-swift",
            "image": "https://assets.euromoneydigital.com/dims4/default/5cc3661/2147483647/strip/true/crop/6240x3276+0+576/resize/1200x630!/quality/90/?url=http%3A%2F%2Feuromoney-brightspot.s3.amazonaws.com%2Fac%2F19%2Fd108f5254a028633aa89e0c920d8%2Fabudhabi-alamy-5march26.jpg",
            "publishedAt": "2026-03-05T13:19:04Z",
            "lang": "en",
            "source": {
                "id": "d2b732fa1316fbd4c93bec75c955888e",
                "name": "GlobalCapital",
                "url": "https://www.globalcapital.com"
            }
        },
        {
            "id": "4d2c7c3810e853c4e4a564b4c28fa762",
            "title": "Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences",
            "description": "The Investor Relations website contains information about Biogen's business for stockholders, potential investors, and financial analysts.",
            "content": "Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)\nNew Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies begin to evaluate this investi... [11687 chars]",
            "url": "https://investors.biogen.com/news-releases/news-release-details/biogen-share-new-sma-data-muscular-dystrophy-association-and-sma",
            "image": "https://investors.biogen.com/sites/g/files/knoqqb90876/files/favicon_0.ico",
            "publishedAt": "2026-03-05T12:32:19Z",
            "lang": "en",
            "source": {
                "id": "00f49970d1b56754e4a692c09e0404d4",
                "name": "Biogen",
                "url": "https://investors.biogen.com"
            }
        }
    ]
}